ŌURA, the company behind the popular smart ring, has secured over $900 million in new funding, catapulting its valuation to approximately $11 billion. This significant investment, led by Fidelity Management & Research Company, highlights the company's explosive growth and solidifies its position as a leader in the preventive health technology space.
The funding news comes as ŌURA reports remarkable business momentum, having now sold over 5.5 million rings since its 2015 debut, with more than half of those sales occurring in the last year alone. The company’s revenue surpassed $500 million in 2024 and is on track to double to $1 billion in 2025, underscoring the massive consumer demand for its health-tracking technology.
Product Innovation and Platform Expansion
Coinciding with its financial milestones, ŌURA has unveiled a significant expansion of its product line, further bridging the gap between wearable technology and comprehensive health management.
Key announcements include:
- Oura Ring 4 Ceramic: A new premium collection crafted from high-performance zirconia ceramic, available in four new colors: Tide, Petal, Cloud, and Midnight. The new ring is priced at $499.
- Health Panels: A groundbreaking in-app feature that allows members to schedule and view results from clinical lab tests directly within the Oura App. In partnership with Quest Diagnostics, this $99 service analyzes over 50 biomarkers, integrating them with the ring's continuous data on sleep, activity, and readiness to provide actionable health insights.
- New Accessories and Features: The company also launched the Oura Ring 4 Charging Case ($99), which holds up to five full charges, and introduced multi-ring support, allowing users to switch between different rings on a single account.
"At ŌURA, we believe that health is deeply personal," said Tom Hale, CEO of ŌURA. "Today’s announcements mark a significant leap forward in empowering our members to take charge of their well-being... With new in-app Health Panels, members receive guidance tailored to their unique biomarker trends and daily patterns."
